Sam Brusco, Associate Editor07.12.22
Abbott has obtained U.S. Food and Drug Administration (FDA) breakthrough status to investigate its deep brain stimulation (DBS) system for treatment-resistant depression (TRD).
Abbott’s DBS system provides personalized, adjustable therapy by implanting leads to targeted brain areas. A pulse generator implanted in the chest connected to the leads produces electrical impulses to modulate abnormal brain activity.
The DBS system has been previously used to control symptoms for Parkinson’s and essential tremor, but according to Abbott evidence suggests implanting electrodes in the brain area that regulates mood can help reduce TRD symptoms.
Certain Abbott DBS systems can be used with NeuroSphere virtual clinic, a connected care technology for communication and remote care/therapy adjustment released last year.
"Breakthrough product development always requires bold thinking and collaboration, and Abbott is fully committed to the journey of providing people with new therapeutic options for their treatment-resistant depression," Pedro Malha, Abbott’s VP of neuromodulation told the press.
Last month at TVT: The Structural Heart Summit, Abbott also shared positive mitral and tricuspid heart valve device data for MitraClip and TriClip.
Abbott’s DBS system provides personalized, adjustable therapy by implanting leads to targeted brain areas. A pulse generator implanted in the chest connected to the leads produces electrical impulses to modulate abnormal brain activity.
The DBS system has been previously used to control symptoms for Parkinson’s and essential tremor, but according to Abbott evidence suggests implanting electrodes in the brain area that regulates mood can help reduce TRD symptoms.
Certain Abbott DBS systems can be used with NeuroSphere virtual clinic, a connected care technology for communication and remote care/therapy adjustment released last year.
"Breakthrough product development always requires bold thinking and collaboration, and Abbott is fully committed to the journey of providing people with new therapeutic options for their treatment-resistant depression," Pedro Malha, Abbott’s VP of neuromodulation told the press.
Last month at TVT: The Structural Heart Summit, Abbott also shared positive mitral and tricuspid heart valve device data for MitraClip and TriClip.